Treatment of Hypopituitarism in Central (Neurogenic) Diabetes Insipidus with Polyuria

Clinical Scenario

This protocol addresses hypopituitarism presenting alongside central (neurogenic) diabetes insipidus — a condition in which the posterior pituitary secretes insufficient antidiuretic hormone (ADH, vasopressin) to meet urine concentration requirements, resulting in significant polyuria.

Central Diabetes Insipidus & Polyuria

The defining feature of this subgroup is ADH deficiency of central origin, leading to failure of urine concentration and persistent polyuria. This distinguishes the scenario from other causes of polyuria and directly determines the therapeutic direction.

Treatment Approach — Overview

Management is built around desmopressin (DDAVP) administered according to individualized therapeutic schedules calibrated to each patient's rest and daily activity needs. The regimen is deliberately tailored rather than uniform — the exact approach, schedule parameters, and administration specifics are detailed in the full protocol.

Full route selection, dosing algorithm, and individualization criteria are available behind the link below.

Instant Access to Structured Evidence-Based Regimens

References

Central (neurogenic) DI occurs when the secretion of ADH (also called vasopressin) by the posterior pituitary is insufficient to meet urine concentration requirements.
When administering DDAVP in DI, we suggest individualized therapeutic schedules.
When treating DI patients in the outpatient setting who have an intact thirst mechanism, clinicians should use the lowest DDAVP dose that allows adequate rest at night and causes minimal disruption of individual daytime activities.

DOI: 10.1210/jc.2016-2118 View source ↗